Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
City of Hope Medical Center
Dana-Farber Cancer Institute
Emory University
St. Jude Children's Research Hospital
Pediatric Brain Tumor Consortium
Pediatric Brain Tumor Consortium
St. Jude Children's Research Hospital
Massachusetts General Hospital
Augusta University
University of Florida
Seattle Children's Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
GlaxoSmithKline
Children's Oncology Group
Memorial Sloan Kettering Cancer Center